EP1572222A1 - Utilisation d'un extrait de la plante argania spinosa - Google Patents

Utilisation d'un extrait de la plante argania spinosa

Info

Publication number
EP1572222A1
EP1572222A1 EP03789179A EP03789179A EP1572222A1 EP 1572222 A1 EP1572222 A1 EP 1572222A1 EP 03789179 A EP03789179 A EP 03789179A EP 03789179 A EP03789179 A EP 03789179A EP 1572222 A1 EP1572222 A1 EP 1572222A1
Authority
EP
European Patent Office
Prior art keywords
arganin
extracts
extract
plant
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03789179A
Other languages
German (de)
English (en)
Inventor
Florence Henry
Louis Danoux
Gilles Pauly
Zoubida Charrouf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Health and Care Products France SAS
Original Assignee
Cognis France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognis France SAS filed Critical Cognis France SAS
Priority to EP03789179A priority Critical patent/EP1572222A1/fr
Publication of EP1572222A1 publication Critical patent/EP1572222A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention is in the field of cosmetic and / or dermopharmaceutical care substances and relates to the use of extracts from the Argania spinosa plant for the production of agents for acne and / or seborrhea, and to preparations with anti-5-alpha-reductase activity.
  • Oily and acne-affected skin shows an increased secretion of skin fat and sebum due to the excessive activity of the sebum glands.
  • the triglycerides contained in the excretions of the sebaceous glands are broken down on the skin by lipases from various microorganisms such as Corynebacterium acnes, Staphylococcus epidermidis and Pytirosporum ovale, and free fatty acids are split off. Some of these free fatty acids lead to the characteristic inflammatory phenomena of the acute acne stage.
  • Saponins especially the triterpene saponins are made up of a tetra- or pentacyclic triterpene aglycon and one or two glycosidically bound sugar chains.
  • the object of the present patent application was to find new applications for well-tolerated active ingredient-rich extracts from renewable vegetable raw materials, in particular looking for active substances for the treatment of acne-infected and seborrhoeic skin.
  • the invention relates to the use of extracts from the plant Argania spinosa (L.) Skeels, hereinafter referred to only as Argania spinosa, for the production of anti-acne agents, for the production of preparations for seborrhea, and for the production of preparations with anti -5-alpha reductase activity.
  • extracts from the Argania spinosa plant can produce preparations which have an excellent action in anti-acne agents and preparations for seborrhea and at the same time have a high skin tolerance. They are therefore ideal for use against oily skin, acne skin and oily scalp, even on sensitive skin types.
  • the preparations produced show a marked anti-5-alpha-reductase activity.
  • Argania spinosa The unwanted, excessive hair growth in women, especially after menopause, is associated with hyperactivity of 5-alpha reductase.
  • the unwanted, often excessive hair growth in certain areas of the face or on the legs can thus be effectively inhibited by using extracts from the Argania spinosa plant.
  • the extracts to be used according to the invention are obtained from plants of the Sapotaceae family, specifically from Argania spinosa (L.) Skeels, hereinafter referred to only as Argania spinosa.
  • This plant is a tree that is found mainly in Morocco on the west side of the Atlas Mountains. It forms berries the size and shape of olives with one or two seeds on its gnarled branches and thorny branches.
  • the nut-tasting oil from the seed kernels serves, among other things, as cooking oil.
  • plant in the sense of the present application means both whole plants and parts of plants (leaves, roots, stem, bark, flowers, fruits, pulp and seeds) and mixtures thereof.
  • Particularly preferred for the extraction of the saponins within the meaning of the invention are the seed kernels of the fruit of this plant, in particular the extraction of the residue from the defatted seed kernels.
  • saponins are basically understood to mean all saponins that can be isolated from the Argania spinosa plant.
  • Saponins which differ in structure from saponins from other plants are obtained from the residue which arises in the extraction of oil from the seeds of Argania spinosa [Charrouf Z., et al .; Phytochemistry, 1992, 31; 2079-2086.]. These are saponins with the names arganin A, arganin B, arganin C, arganin D, arganin E, arganin F and misaponin A. The saponins arganin G, arganin H and arganin J [Oulad -Ali A., et al .; J Nat. Prod .; 1996, 59, 193-195.].
  • the aglycon of these saponins has the structure (I) shown below; the saponins mentioned differ in the sugar units at Rl and R3 or by a hydroxyl group on R2.
  • R3 is a tetrasaccharide and Rl is a mono- or disaccharide (e.g. 1,6-diglucose for arganin A and B).
  • the saponins according to the invention show low toxicity in toxicological tests on mice and rats. Compared to other saponins such as those from Gypsophila paniculata, the inventors were also able to demonstrate a significantly lower toxicity by tests on human fibroblasts.
  • the saponins to be used according to the invention correspond to arganin A, arganin B, arganin C, arganin D, arganin E, arganin F, misaponin A, and arganin G, arganin H, and arganin J. They can be a mixture of two or more, or a pure substance in the cosmetic and or pharmaceutical preparation are used. Mixtures of arganin A, arganin B, arganin C, arganin D, arganin E, arganin F, misaponin A are particularly preferred, it being possible for the proportions of the saponins in the mixtures to vary. Extracts containing a high amount of arganin A are preferably used. The use according to the invention of extracts with at least 6% by weight, preferably 8% by weight and in particular at least 10% by weight of arganin A - based on the dry weight of the extract - has been distinguished by its particularly pronounced effects.
  • proteins are to be understood as those which can be isolated from the Argania spinosa plant.
  • the extraction of the seed kernels, in particular the degreased seed kernels, is preferred after the oil extraction.
  • a particular embodiment of the invention is preparations which contain native proteins which are obtained from an extract of the seed kernels, in particular the defatted seed kernels from Argania spinosa.
  • the preferred extraction of the defatted seed kernels means that the residue - a type of cake - is preferably extracted from the extraction for oil production from the sanitary kernels of Argania spinosa.
  • This residue which is preferably to be extracted from the extraction for oil extraction, contains 3 to 10% by weight of residual oil.
  • the proteins according to the invention are separated as completely as possible from the remaining oil from this residue.
  • other substances naturally occurring in the Argania spinosa plants can also be extracted, which can be extracted under the same conditions.
  • the preparations according to the invention contain native proteins which, by aqueous extraction at a pH value of less than or equal to 12, preferably between 3.5 and 6.5, in particular either between 5.5 and 6.5 or between 3 , 5 and 5.5 and optionally a subsequent drying, for example, spray or freeze drying.
  • the selected pH range depends on the protein fraction to be isolated.
  • the native proteins that can be extracted from the Argania spinosa plant, particularly from the plant's kernels, can have molecular weights between 10,000 Da and greater than 500,000 Da. They can preferably be divided into the following groups of molecular weight ranges. Native proteins with a molecular weight greater than 500,000 Da, native proteins with molecular weight in the range from 170,000 to 250,000 Da and native proteins with molecular weight in the range from 10,000 to 18,000 Da can be extracted.
  • further embodiments of the invention relate, on the one hand, to preparations which contain native proteins whose molecular weight is greater than 500,000 Da, to preparations which contain native proteins whose molecular weight is in the range from 170,000 Da to 250,000 Da, preferably in the range from 170,000 Da to 210,000 Da and preparations containing native proteins whose molecular weight is in the range from 10,000 to 18,000, preferably in the range from 13,000 to 16,000.
  • the proportion of proteins in the extract used according to the invention should preferably be at least 3% by weight, preferably at least 4% by weight and in particular at least 5% by weight, based on the dry weight of the extract
  • the extracts to be used according to the invention are produced by customary methods of extracting plants or parts of plants.
  • suitable conventional extraction methods such as maceration, remaceration, digestion, movement maceration, vortex extraction, ultrasound extraction, countercurrent extraction, percolation, repercolation, evacolation (extraction under reduced pressure), diacolation and solid-liquid extraction under continuous reflux which is carried out in a Soxhlet extractor, which is familiar to a person skilled in the art and in principle all can be used, is exemplary of Hager's Handbook of Pharmaceutical Practice, (5th Edition, Vol. 2, pp. 1026-1030, Springer Verlag, Berlin- Heidelberg-New-York 1991).
  • Fresh or dried plants or parts of plants can be used as the starting material, but it is usually assumed that defatted plants and / or parts of plants are used which can be mechanically comminuted before extraction. All the grinding methods known to the person skilled in the art are suitable here, for example crushing with a mortar.
  • the extracts used are obtained by extracting the Stem, root, leaf, flower or fruit. The extraction of the seed kernels is particularly preferred.
  • Organic solvents, water or mixtures of organic solvents and water, in particular low-molecular alcohols, esters, ketones or halogen-containing hydrocarbons with more or less high water contents (distilled or not distilled), preferably aqueous, alcoholic solutions of one temperature can preferably be used as solvents for carrying out the extractions of over 20 ° C, (hereinafter referred to as room temperature). Extraction with water, methanol, ethanol, acetone, propylene glycols, polyethylene glycols, ethyl acetate, dichloromethane, trichloromethane and mixtures thereof is particularly preferred. The extraction is usually carried out at 20 to 100 ° C, preferably at 20 to 85 ° C, especially at room temperature.
  • the extraction takes place under an inert gas atmosphere in order to avoid oxidation of the ingredients of the extract.
  • the extraction times are determined by the person skilled in the art depending on the starting material, the extraction process, the extraction temperature, the ratio of solvent to raw material, etc. set.
  • the crude extracts obtained can optionally be subjected to further customary steps, such as purification, concentration and / or decolorization. If desired, the extracts produced in this way can, for example, be subjected to a selective separation of individual undesirable ingredients.
  • the extraction can be carried out to any desired degree of extraction, but is usually carried out until exhaustion.
  • the present invention includes the knowledge that the extraction conditions and the yields of the final extracts can be selected depending on the desired field of use. If desired, the extracts can then be subjected to spray or freeze drying, for example.
  • the extracts of this plant contain 10 to 99% by weight of saponins, preferably 15 to 70% by weight.
  • the amount of plant extracts used in the anti-acne agents and preparations for seborrhea, as well as preparations with anti-5-alpha-reductase activity, depends on the concentration of the individual ingredients.
  • the total amount of the plant extract which is contained in the preparations is generally 0.01 to 25% by weight, preferably 0.03 to 5% by weight, in particular 0.03 to 0.4% by weight on the final preparation.
  • the plant extracts used preferably contain proteins and saponins in combination in the quantitative ranges described.
  • extracts from the Argania spinosa plant for the production of anti-acne agents, preparations for seborrhea and preparations with anti-5-alpha-reductase activity results in cosmetic and / or pharmaceutical preparations such as, for example, creams, gels, lotions, alcoholic and aqueous / alcoholic solutions, emulsions, hair shampoos, hair lotions, foam baths, shower baths, wax / fat masses, stick preparations, powders or ointments.
  • cosmetic and / or pharmaceutical preparations such as, for example, creams, gels, lotions, alcoholic and aqueous / alcoholic solutions, emulsions, hair shampoos, hair lotions, foam baths, shower baths, wax / fat masses, stick preparations, powders or ointments.
  • agents can also be used as further auxiliaries and additives, mild surfactants, oil bodies, emulsifiers, pearlescent waxes, consistency agents, thickeners, superfatting agents, stabilizers, polymers, silicone compounds, fats, waxes, lecithins, phospholipids, biogenic active ingredients, UV light protection factors, antioxidants, film formers, swelling agents, Contain hydrotropes, solubilizers, preservatives, perfume oils, dyes and the like.
  • mild surfactants oil bodies, emulsifiers, pearlescent waxes, consistency agents, thickeners, superfatting agents, stabilizers, polymers, silicone compounds, fats, waxes, lecithins, phospholipids, biogenic active ingredients, UV light protection factors, antioxidants, film formers, swelling agents, Contain hydrotropes, solubilizers, preservatives, perfume oils, dyes and the like.
  • the total proportion of auxiliaries and additives can be 1 to 70, preferably 20 to 50 and in particular 5 to 40% by weight, based on the final preparation of the cosmetic and / or pharmaceutical preparations.
  • the preparations can be produced by customary cold or hot processes; the phase inversion temperature method is preferably used.
  • Testosterone [4- 14 C] testosterone (Amersham, CFA129, 56 mCi / mmole), 250 nCi / epidermis
  • the epidermis was precultivated on 24-position plates for 24 hours.
  • the tests with the products and the reference substance finasteride (10 ⁇ M) were carried out in triplicate (3 epidermis approaches per experiment).
  • the media of the subepidermis were renewed and replaced with 300 ⁇ l of fresh culture medium.
  • 100 ⁇ l of radioactively labeled testosterone solution was applied to the top (cornea) of the epidermis (TO). After a further 24 hours, the subepidermis medium was removed for analysis.
  • the viability of the keratinocytes in the different epidermis samples was examined at the end of the experiment using the MTT method.
  • the steroids contained in the culture medium were extracted for analysis of the metabolism and separated into their molecular derivatives by thin-layer chromatography (on silica gel).
  • the amount of testosterone transformed was determined by radioactive counting of the different spots with a phosphoimager.
  • Table 2 Influence of the treatment with Argania extract on the production of DHT. Analysis by phosphor imager in connection with the accumulated radioactivity
  • the examined extract shows a clear reduction in the production of DHT - 39 and 26% inhibition.
  • a significant inhibition of 5-alpha-reductase activity can already be detected without toxic effects influencing the survivability of the cells (determined in the MTT test).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un extrait végétal d'argania spinosa dans la production d'agents anti-acné, de préparations servant à combattre la séborrhée et de produits de lutte contre l'activité 5-alpha réductase, l'extrait contenant des protéines, de la saponine, et notamment de l'arganine A.
EP03789179A 2002-12-18 2003-12-09 Utilisation d'un extrait de la plante argania spinosa Withdrawn EP1572222A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03789179A EP1572222A1 (fr) 2002-12-18 2003-12-09 Utilisation d'un extrait de la plante argania spinosa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02293130 2002-12-18
EP02293130A EP1430900A1 (fr) 2002-12-18 2002-12-18 Utilisation d'un extrait de la plante Argania Spinosa
EP03789179A EP1572222A1 (fr) 2002-12-18 2003-12-09 Utilisation d'un extrait de la plante argania spinosa
PCT/EP2003/013921 WO2004054597A1 (fr) 2002-12-18 2003-12-09 Utilisation d'un extrait vegetal d'argania spinosa

Publications (1)

Publication Number Publication Date
EP1572222A1 true EP1572222A1 (fr) 2005-09-14

Family

ID=32338196

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02293130A Withdrawn EP1430900A1 (fr) 2002-12-18 2002-12-18 Utilisation d'un extrait de la plante Argania Spinosa
EP03789179A Withdrawn EP1572222A1 (fr) 2002-12-18 2003-12-09 Utilisation d'un extrait de la plante argania spinosa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02293130A Withdrawn EP1430900A1 (fr) 2002-12-18 2002-12-18 Utilisation d'un extrait de la plante Argania Spinosa

Country Status (5)

Country Link
US (1) US20060083794A1 (fr)
EP (2) EP1430900A1 (fr)
JP (1) JP2006511524A (fr)
KR (1) KR20050085819A (fr)
WO (1) WO2004054597A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711194B1 (fr) 2003-10-24 2009-11-25 Cognis France, S.A.S. Extrait vegetal et utilisation pharmaceutique et cosmetique correspondante
US8863168B2 (en) * 2005-11-14 2014-10-14 Rovi Guides, Inc. Media control system with viewer rewards
FR2958163B1 (fr) 2010-03-31 2014-06-13 Fabre Pierre Dermo Cosmetique Preparation issue d'une culture in vitro de cellules dedifferencieres non elicitees d'arganier, leur utilisation pour le traitement du vieillissement cutane, de l'inflammation et de la cicatrisation, et leur obtention.
KR101142445B1 (ko) * 2010-08-18 2012-05-08 정명우 아르간 오일 함유 치약조성물
CN104707042A (zh) * 2015-03-17 2015-06-17 唐学田 一种治疗痤疮的中药组合物
US20200197296A1 (en) * 2018-12-19 2020-06-25 Mary Kay Inc. Topical compositions and methods
JP2023162457A (ja) * 2020-09-09 2023-11-09 株式会社Adeka アルガン抽出物の製造方法、アルガン抽出物、発毛促進剤、脱毛予防剤、及び毛周期調節剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625211A (ja) * 1992-07-13 1994-02-01 Mitsubishi Kasei Corp フラボンカルボン酸誘導体
US5773005A (en) * 1995-06-09 1998-06-30 Takahashi; Hidehiko Purified flavonoid and diterpene 5α-reductase inhibitors from thuja orientalis for androgen-related diseases
EP1213024A1 (fr) * 2000-12-06 2002-06-12 Laboratoires Serobiologiques Composition cosmétique et/ou dermopharmaceutique conténant de protéines natives de Argania spinosa
EP1213025A1 (fr) * 2000-12-06 2002-06-12 Laboratoires Serobiologiques(Societe Anonyme) Composition cosmétique et/ou dermopharmaceutique conténant un extrait obtenu à partir de feuilles d'Argania spinosa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004054597A1 *

Also Published As

Publication number Publication date
US20060083794A1 (en) 2006-04-20
WO2004054597A1 (fr) 2004-07-01
JP2006511524A (ja) 2006-04-06
EP1430900A1 (fr) 2004-06-23
KR20050085819A (ko) 2005-08-29

Similar Documents

Publication Publication Date Title
DE60030766T2 (de) Verwendung eines extraktes der gattung vaccinium als anti-glykations-agens
DE102006062929B3 (de) Verwendung pflanzlicher Extrakte als Wirkstoff zur HAS2-Stimulierung in einer kosmetischen Zusammensetzung
DE4241487C2 (de) Neue Extrakte von Cucurbita sp., Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln und in der Kosmetik
EP0993822B1 (fr) Agent accélérant la production de céramides
DE69831486T2 (de) Antiproliferative zubereitungen
DE10164893B4 (de) Verfahren zur Herstellung von Artischockenblätterextrakten und so erhaltene Artischockenblätterextrakte
EP0084546B1 (fr) Produits pour les soins des cheveux
DE202015006894U1 (de) Zusammensetzungen enthaltend einen Extrakt aus Echinacea und Linolsäurederivate
EP3033073B1 (fr) Préparation pour protéger contre le vieillissement de peau
DE69932383T2 (de) Biologisch aktive Labdan-oder Labdenderivate aus Cistus
DE10308162A1 (de) Verfahren zur Herstellung von Flavonoid-haltigen Zusammensetzungen und ihre Verwendung
DE102010038235A1 (de) Neue Verwendung eines Extraktes aus der Orchidee Vanda coerulea
WO2004054597A1 (fr) Utilisation d'un extrait vegetal d'argania spinosa
AT393623B (de) Verfahren zur herstellung von hautpflegenden kompositionen mit keratolytischer und entzuendungshemmender wirkung
Rawat et al. Preventive role of Sapindus species in different neurological and metabolic disorders
EP1715879A1 (fr) Extraits d'oignons
KR20180018625A (ko) 만수국아재비 추출물을 함유하는 아토피 피부염 개선용 화장료 조성물
WO2020182822A1 (fr) Extrait de bulbe de safran pour le traitement d'inflammations
DE60114940T2 (de) Verwendung eines Iridacea-Extrakts in einer Zusammensetzung für die Stimulierung der Immunabwehr
CH710983B1 (de) Kosmetikzusammensetzung mit Safranblütenblattextrakt.
JPH05500823A (ja) 凍結乾燥した刺激性の少ないハイブリッドかぼちゃ及びそれを含有する医薬
WO2004112813A1 (fr) Extraits de litchi sinensis renfermant des oligomeres proanthocyanidine
DE10151649A1 (de) Verwendung von Lanostanen als Inhibitoren von 3alpha-Hydroxysteroid-Dehydrogenase und Cyclooxygenasen
US11684563B2 (en) Plant derived active ingredient comprising plant extracts
US8617622B2 (en) Extracts and compounds from Ficus benghalensis for increasing hair growth and decreasing hair loss

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COGNIS FRANCE, S.A.S.

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20070305

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 19/00 20060101ALI20080418BHEP

Ipc: A61P 17/08 20060101ALI20080418BHEP

Ipc: A61K 36/44 20060101AFI20080418BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080927